blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2903613

EP2903613 - PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF IRAK4 ACTIVITY [Right-click to bookmark this link]
Former [2015/33]INHIBITORS OF IRAK4 ACTIVITY
[2017/20]
StatusNo opposition filed within time limit
Status updated on  28.09.2018
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  20.10.2017
FormerGrant of patent is intended
Status updated on  01.05.2017
FormerExamination is in progress
Status updated on  25.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2015/33]
Inventor(s)01 / SEGANISH, Michael W.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
02 / HANISAK, Jennifer
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
03 / LI, Guoqing
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
04 / ZHANG, Rui
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
05 / TANG, Haiqun
2000 Galloping Hill Road
Kenilworth, New Jersey 07033 / US
 [2015/33]
Representative(s)Jaap, David Robert, et al
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
[N/P]
Former [2017/47]Jaap, David Robert, et al
Merck Sharp & Dohme Corp.
European Patent Department
Hertford Road
Hoddesdon, Hertfordshire EN11 9BU / GB
Former [2015/33]Buchan, Gavin MacNicol, et al
Merck & Co., Inc.
European Patent Department
Hertford Road
Hoddesdon, Hertfordshire EN11 9BU / GB
Application number, filing date13845052.303.10.2013
[2015/33]
WO2013US63173
Priority number, dateUS201261710958P08.10.2012         Original published format: US 201261710958 P
[2015/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014058691
Date:17.04.2014
Language:EN
[2014/16]
Type: A1 Application with search report 
No.:EP2903613
Date:12.08.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 17.04.2014 takes the place of the publication of the European patent application.
[2015/33]
Type: B1 Patent specification 
No.:EP2903613
Date:22.11.2017
Language:EN
[2017/47]
Search report(s)International search report - published on:US17.04.2014
(Supplementary) European search report - dispatched on:EP18.03.2016
ClassificationIPC:A61K31/44, A61K31/415, C07D231/02
[2015/33]
CPC:
C07D409/14 (EP,US); A61K31/4439 (EP,US); A61K31/444 (EP,US);
A61K31/496 (EP,US); A61K31/497 (EP,US); A61K31/506 (EP,US);
A61K31/5377 (EP,US); A61K45/06 (EP,US); C07D401/12 (EP,US);
C07D401/14 (EP,US); C07D405/14 (EP,US); C07D417/14 (EP,US) (-)
C-Set:
A61K31/4439, A61K2300/00 (US,EP);
A61K31/444, A61K2300/00 (EP,US);
A61K31/496, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (EP,US);
A61K31/5377, A61K2300/00 (US,EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/33]
Extension statesBA08.05.2015
ME08.05.2015
TitleGerman:PYRAZOLDERIVATE ZUR VERWENDUNG ALS INHIBITOREN DER IRAK4-AKTIVITÄT[2017/20]
English:PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF IRAK4 ACTIVITY[2017/20]
French:COMPOSÉS PYRAZOLIQUES UTILES EN TANT QU'INHIBITEURS D'ACTIVITÉ D'IRAK4[2017/20]
Former [2015/33]INHIBITOREN DER IRAK4-AKTIVITÄT
Former [2015/33]INHIBITORS OF IRAK4 ACTIVITY
Former [2015/33]INHIBITEURS D'ACTIVITÉ D'IRAK4
Entry into regional phase08.05.2015National basic fee paid 
08.05.2015Search fee paid 
08.05.2015Designation fee(s) paid 
08.05.2015Examination fee paid 
Examination procedure08.05.2015Examination requested  [2015/33]
07.10.2016Amendment by applicant (claims and/or description)
24.11.2016Despatch of a communication from the examining division (Time limit: M04)
31.03.2017Reply to a communication from the examining division
02.05.2017Communication of intention to grant the patent
05.09.2017Fee for grant paid
05.09.2017Fee for publishing/printing paid
05.09.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.11.2016
Opposition(s)23.08.2018No opposition filed within time limit [2018/44]
Fees paidRenewal fee
07.10.2015Renewal fee patent year 03
07.10.2016Renewal fee patent year 04
10.10.2017Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.10.2013
AL22.11.2017
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IS22.03.2018
[2020/33]
Former [2020/32]HU03.10.2013
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IS22.03.2018
Former [2020/31]HU03.10.2013
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2020/28]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2020/16]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2019/28]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/52]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/40]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/39]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
IT22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/37]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/35]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/24]AT22.11.2017
ES22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
RS22.11.2017
SE22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/22]ES22.11.2017
FI22.11.2017
LT22.11.2017
NL22.11.2017
NO22.02.2018
Documents cited:Search[A]US8148411  (BOTHE ULRICH [DE], et al) [A] 1-10 * column 7, line 55 - column 9, line 49; examples 1.10, 1.14, 1.16; claims 1, 5 *;
 [A]WO2011043371  (ASTELLAS PHARMA INC [JP], et al) [A] 1-10 * several compounds of the description, for example compounds 20 (page 85), 25 (page 86), 36 and 38 (page 87), 20 (page 105), 157 (page 116), etc.;; claims 1, 7, 8 *;
 [A]US2011306589  (BLEICHER KONRAD [DE], et al) [A] 1-10 * claims 1, 54 *
International search[Y]US2012115861  (CALDERINI MICHEL [DE], et al);
 [Y]US8148411  (BOTHE ULRICH [DE], et al);
 [A]WO2012129258  (MERCK SHARP & DOHME [US], et al);
 [YP]WO2013042137  (AURIGENE DISCOVERY TECH LTD [IN], et al)
 [Y]  - WANG, Z ET AL., "IRAK-4 Inhibitors for Inflammation.", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 9, no. 8, (2009), pages 724 - 737, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182414, (20140110), XP055067855

DOI:   http://dx.doi.org/10.2174/156802609789044407
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.